News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News Laquinimod failure is bad news for Teva's MS hopes Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.
News AZ hopes to boost respiratory pipeline with Pieris deal AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.
News Diagnostics lag is holding back new therapies, says study Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
